Exhibit 99.1

                              FOR IMMEDIATE RELEASE

      BOSTON LIFE SCIENCES NAMES NEW PRESIDENT AND CHIEF OPERATING OFFICER

   Dr. Robert J. Rosenthal will provide substantial operating experience and
                               management depth.

July 10, 2002--Boston, Ma. --Boston Life Sciences, Inc. (NASDAQ: BLSI) announced
the appointment of Dr. Robert J. Rosenthal as President and Chief Operating
Officer. A proven executive with twenty years of experience in building
shareholder value, Dr. Rosenthal led the acquisition and integration of the
PerkinElmer Analytical Instruments Division into EG&G. As president of the
combined division, with revenues in excess of $800 million, he focused on
serving the needs of a wide range of customers including the pharmaceutical and
biotechnology sectors. Prior to this responsibility, Dr. Rosenthal was President
& CEO of Thermo Optek Corporation an analytical instrument company. Sales under
his leadership rose from $212 million to $550 million, and pretax profits
accelerated to over $80 million from $35 million. Earlier in his career, Dr.
Rosenthal was the President of Nicolet Instrument Corporation, a supplier of
analytical tools for research and development to several industries including
biotechnology. In the course of his career, he integrated successfully the
acquisition of a dozen companies with an aggregate value over $1 billion.

David Hillson, the Chairman and CEO of Boston Life Sciences commented, "BLSI
needs greater management depth now that our company is completing its
transformation from a research & development, pre-clinical biotech entity into a
clinical product vehicle. Most of its science is being readied for human trials
and potential partnering. We believe Bob's multi-faceted successful operating
experience will provide us with a structured and focused effort aimed at
translating our well-recognized, innovative technological accomplishments into
relevant commercial opportunities." Hillson went on to say, "We have looked for
the addition of key senior management strength for quite some time. Bob, a
seasoned operating executive, who has an outstanding profit orientation will
bring an enhanced sense of discipline to the new phase that lies ahead for BLSI.
In this exceedingly difficult environment for biotech funding where the emphasis
is upon rapid development of commercially realizable values, Bob's record of
pragmatic, turnaround management, will help channel our efforts more efficiently
toward enhancing shareholder value."

Dr. Rosenthal stated, "I am delighted to join a management team that I believe
has created an enviable record of exposure to exceptional technologies aimed at
addressing unmet diagnostic and therapeutic needs for major disorders like
cancer, central nervous system trauma, Parkinson's disease and Attention Deficit
Hyperactivity Disorder. Our challenge is to harness these achievements for the
creation of long-term economic values as we move as efficiently as possible
through the clinical and approval phases that lie ahead."

Bob Rosenthal holds a B.S. in Chemistry from the University of Maryland, an M.S.
in Chemistry from State University of New York (Buffalo) and a Ph.D. in Physical
Chemistry from Emory University. He spent a post-doctorate year in Germany as a
fellow and guest scientist of the Alexander von Humboldt Foundation, followed by
a year at UCLA as a post-doctorate fellow. Bob, who lives in the Boston area,
also holds an AEA Executive MBA from Stanford University.

BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease
(PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments
for cancer, autoimmune disease, and central nervous system disorders. BLSI's
products in development include: ALTROPANE(TM) and FLUORATEC(TM) radioimaging
agents for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring
anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine,
nerve growth factors for the treatment of acute and chronic CNS disorders; novel
therapies for the treatment of PD and ADHD; and transcription factors that may
control the expression of molecules associated with autoimmune disease and
allergies.

Statements made in this press release other than statements of historical fact
represent forward-looking statements. Such statements include, without
limitation, statements regarding expectations or beliefs as to future results or
events, such as the expected timing and results of clinical trials, discussions
with regulatory agencies, schedules of IND, NDA and all other regulatory
submissions, the timing of product introductions, the possible approval of
products, and the market size and possible advantages of the Company's products.
All such forward-looking statements involve substantial risks and uncertainties,
and actual results may vary materially from these statements. Factors that may
affect future results include: the availability and adequacy of financial
resources, the ability to obtain intellectual property protection, delays in the
regulatory or development processes, results of scientific data from clinical
trials, the outcome of discussions with potential partners, regulatory
decisions, market acceptance of the Company's products, and other possible risks
and uncertainties that have been noted in reports filed by the Company with the
Securities and Exchange Commission, including the Company's Annual Report on
Form 10-K.

  For further information, please contact:

                                               Corporate
                                               David Hillson
                                               President & CEO
                                               dhillson@bostonlifesciences.com
                                               617.425.0200